All In Biotech

Drug Trial Radar · NCT02327169

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies

Last checked: Nov 19, 2026Latest source record: Feb 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

81

Actual

Start

Jan 14, 2015

Primary completion

Jul 2, 2018

Study completion Jul 2, 2018

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Dec 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in participants with advanced nonhematologic malignancies.

Conditions

  • Advanced Nonhematologic Malignancies

Interventions

  • MLN2480Drug

    MLN2480 tablets.

  • MLN0128Drug

    MLN0128 capsules.

  • AlisertibDrug

    Alisertib tablets.

  • PaclitaxelDrug

    Paclitaxel IV infusion.

  • CetuximabDrug

    Cetuximab IV infusion.

  • IrinotecanDrug

    Irinotecan IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1, Cycle 1 through 30 days after the last dose of study drug (up to 13 months)
  2. Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: From Day 1, Cycle 1 through 30 days after the last dose in Cycle 1 (up to 8 weeks)
  3. Maximum Tolerated Dose (MTD) for MLN2480Time frame: Day 1, Cycle 1 up to 28 days
  4. Recommended Phase 2 Dose (RP2D) of MLN2480Time frame: Day 1, Cycle 1 up to 28 days

Locations

14 sites in 4 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Institut Bergonie

    Bordeaux, Gironde, France

  • Institut Claudius Regaud-Oncopole

    Toulouse, Haute Garonne, France

  • Institut Gustave Roussy

    Villejuif, Val De Marne, France

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • START Madrid. Fundacion Jimenez Diaz

    Madrid, Spain

  • Hospital Clinico Universitario Virgen de la Victoria

    Málaga, Spain

  • Sarah Cannon Research Institure UK

    London, Greater London, United Kingdom

  • The Chrisie

    Manchester, Greater Manchester, United Kingdom

  • Churchill Hospital

    Oxford, Oxfordshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.